Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections

Autor:	Sayan M; Clinical Laboratory, PCR Unit, Kocaeli University School of Medicine, Kocaeli, Turkey; Research Center of Experimental, Health Sciences Near East University, Northern Cyprus, Özgüler M; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey, Sarıgül Yıldırım F; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey, Yıldırmak T; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Okmeydanı Training and Research Hospital, İstanbul, Turkey, Gündüz A; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Şişli Etfal Training and Research Hospital, İstanbul, Turkey, Dokuzoğuz B; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Ankara Training and Research Hospital, Ankara, Turkey, Çelen MK; Department of Infectious Diseases and Clinical Microbiology, Dicle University School of Medicine, Diyarbakır, Turkey, İnan D; Department of Infectious Diseases and Clinical Microbiology, Akdeniz University School of Medicine, Antalya, Turkey, Heper Y; Department of Infectious Diseases and Clinical Microbiology, Uludağ University School of Medicine, Bursa, Turkey, Ersöz G; Department of Infectious Diseases and Clinical Microbiology, Mersin University School of Medicine, Mersin Turkey, Karaoğlan İ; Department of Infectious Diseases and Clinical Microbiology, Gaziantep University School of Medicine, Gaziantep, Turkey, Ceran N; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey, Deveci A; Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey, Öztürk S; Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, İstanbul, Turkey, Sayın Kutlu S; Department of Infectious Diseases and Clinical Microbiology, Pamukkale University School of Medicine, Denizli, Turkey, Özkan Özdemir H; Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bozyaka Training and Research Hospital, İzmir, Turkey, Akbulut A; Department of Infectious Diseases and Clinical Microbiology, Fırat University School of Medicine, Elazığ, Turkey, Yazıcı S; Clinic of Infectious Diseases and Clinical Microbiology, Medeniyet University, Göztepe Training and Research Hospital, İstanbul, Turkey, Şener A; Department of Infectious Diseases and Clinical Microbiology, Onsekiz Mart University School of Medicine, Çanakkale, Turkey, Çağatay A; Department of Infectious Diseases and Clinical Microbiology, İstanbul University School of Medicine, İstanbul, Turkey, Ünal S; Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey
Jazyk:	angličtina
Zdroj:	Balkan medical journal [Balkan Med J] 2020 Apr 10; Vol. 37 (3), pp. 125-130. Date of Electronic Publication: 2020 Feb 28.
DOI:	10.4274/balkanmedj.galenos.2020.2019.5.89
Abstrakt:	Background: Because of their similar modes of transmission, the simultaneous infection of viral hepatitis and human immunodeficiency virus are increasingly seen as a big problem related to human health. Aims: To determine the drug mutations in hepatitis B virus and/or hepatitis C virus co-infected human immunodeficiency virus-1 patients in Turkey. Study Design: Retrospective cross-sectional study. Methods: The present study was conducted between 2010 and 2017. HBsAg, anti-hepatitis C virus, and anti-human immunodeficiency virus were tested with ELISA. All anti-human immunodeficiency virus positive results by ELISA were verified for anti-human immunodeficiency virus positivity by a Western blot test, and Anti-human immunodeficiency virus positive patients with HBsAg and/or anti-hepatitis C virus positivity were included in the study. Subtyping and genotypic resistance analyses were performed by population sequencing of the viral protease and reverse transcriptase regions of the human immunodeficiency virus-1 pol gene. Results: We detected 3896 human immunodeficiency virus-1 positive patients whose sera were sent from numerous hospitals across the country to our polymerase chain reaction unit for detection of drug resistance mutations and whose molecular laboratory tests were completed. Viral hepatitis co-infections were detected in 4.3% (n=170) of patients. Hepatitis B virus and hepatitis C virus co-infection were observed in 3.2% and 0.5% of all human immunodeficiency virus-1 infected patients, respectively. The major human immunodeficiency virus-1 subtype detected was group M, subtype B (62.9%). However, 13.5% of drug resistance mutation motifs were found in human immunodeficiency virus-1 genomes of patients included in the study. Conclusion: Due to similar transmission routes, HIV1 patients are at risk of hepatitis B and C virus co-infection. However, antiretroviral drug resistance mutation model is similar to patients with hepatitis negative.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF